Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q1 revenue rises 9.3% to $558.6 million; EPS $3.67 vs. $3.20

Positive Impact 4 of 5 earnings Written later

Medpace reported first-quarter 2025 revenue of $558.6 million and GAAP diluted EPS of $3.67, both up from the prior-year quarter, and issued 2025 guidance of $2.140 billion to $2.240 billion in revenue and $12.26 to $13.04 in diluted EPS. Its board also raised the stock repurchase program by $1.0 billion on April 17, 2025, and the company amended its $600 million unsecured credit facility with PNC Bank.

Key points

  • Q1 2025 revenue was $558.6 million, up 9.3% from $511.0 million; GAAP net income was $114.6 million, or $3.67 per diluted share, versus $3.20 a year earlier.
  • Net new business awards fell 18.8% to $500.0 million, giving a 0.90x book-to-bill ratio; backlog decreased 2.1% to $2,846.0 million.
  • Board approved a $1.0 billion increase to the stock repurchase program on April 17, 2025; $344.8 million remained under the program at March 31, 2025.
  • Full-year 2025 guidance: revenue of $2.140 billion to $2.240 billion and GAAP diluted EPS of $12.26 to $13.04.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECApr 21, 2025, 4:15 PM ET
Accession number0001668397-25-000056

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.